Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial - Rodrigues, Manuel; Vanoni, Giulia; Loap, Pierre; Dubot, Coraline; Timperi, Eleonora; Minsat, Mathieu; Bazire, Louis; Durdux, Catherine; Fourchotte, Virginie; Laas, Enora; Pouget, Nicolas; Castel-Ajgal, Zahra; et al. (Nature communications, 2023)
Keywords: 13/31; 13/51; 38; 45; 45/23; 631/67/580; 692/4028/67/1517/1371; 692/53/2423; Antigen presentation; Antigens; B7-H1 Antigen; Brachytherapy; Cancer; CD11c antigen; CD3 antigen; CD4 antigen; CD8 antigen; Cell death; Cervical cancer; Chemoradiotherapy; Chemotherapy; Female; Foxp3 protein; Health risks; Humanities and Social Sciences; Humans; Immunological tolerance; Immunotherapy; Lung Neoplasms - drug therapy; Lymphocytes; Lymphocytes T; Macrophages; Monoclonal antibodies; multidisciplinary; Myeloid cells; Nivolumab - therapeutic use; Patients; PD-1 protein; PD-L1 protein; Phagocytosis; Programmed Cell Death 1 Receptor; Radiation therapy; Response rates; Risk assessment; Science; Science (multidisciplinary); Survival; Targeted cancer therapy; Tumor cells; Tumors; Uterine Cervical Neoplasms - drug therapy